DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 3750--------------------------------------------------
       Roche touts Ocrevus benefits in treating MS early--competing wit
       h Kesimpta
       By: agate Date: August 21, 2022, 1:06 am
       ---------------------------------------------------------
       From FiercePharma (April 21, 2021)--"Roche, playing defense
       against Novartis' Kesimpta, touts Ocrevus benefits in treating
       MS early":
  HTML https://www.fiercepharma.com/pharma/roche-playing-against-novartis-kesimpta-touts-ocrevus-benefits-treating-ms-early
       Although this article is over a year old, it contains an
       interesting bit of data that surprised me:
       [quote][font=PT Serif]About 80% of patients adhered to
       twice-yearly dosing of Ocrevus after their second year of
       treatment. That was compared with 54% for other IV drugs, 35%
       for intramuscular and under-the-skin injectables, and 55% for
       orals.[/font][/size][/quote]Only 35% of the MS patients on the
       intramuscular and under-the-skin injectables stay on them after
       the second year.  Does this dismal adherence indicate a vote of
       no-confidence in those drugs, or is it more that people find
       doing the injections to be difficult?[size=25px]
       *****************************************************